ESMO: Moderna's mRNA solid tumour vaccine shows early promise - Clinical Trials Arena
Moderna’s mRNA cancer vaccine for solid tumours shows early immune response in Phase I/II trial, with 8/16 patients not seeing tumour growth. The vaccine targets PD-L1 and IDO1 proteins, aiming to activate immune cells against cancer. Moderna plans to present interim data at the European Society of Medical Oncology meeting on 14 September.
Related Clinical Trials
Reference News
Moderna's mRNA-4359 vaccine, designed to activate the immune system against cancer cells, shows promising early results in a phase-one trial with 19 advanced solid tumour patients, with 8 showing no tumour growth and no new tumours. The vaccine is well tolerated without serious adverse effects, and the study now focuses on melanoma and non-small-cell lung cancer patients.
A new mRNA cancer vaccine, developed by Moderna, shows promise in halting tumor growth in advanced melanoma and lung cancer patients. Early trial results indicate no tumor growth in 8 out of 16 evaluated patients, with no serious side effects. The treatment aims to stimulate the immune system to recognize and fight cancer cells.
Moderna's mRNA-4359 vaccine, targeting advanced melanoma and solid tumours, shows potential in early trials, with 8 out of 16 patients experiencing no tumour growth. The treatment, using mRNA tech similar to COVID-19 vaccines, primes the immune system to recognize and fight cancer cells, with no serious side effects reported. The results, to be presented at a European oncology conference, mark an important step towards a new cancer treatment.
Moderna’s mRNA cancer vaccine for solid tumours shows early immune response in Phase I/II trial, with 8/16 patients not seeing tumour growth. The vaccine targets PD-L1 and IDO1 proteins, aiming to activate immune cells against cancer. Moderna plans to present interim data at the European Society of Medical Oncology meeting on 14 September.